The U.S. Food and Drug Administration has initiated a policy shift by publicly releasing over 200 complete response letters (CRLs) issued between 2020 and 2024 for drugs that were eventually approved. This move, aimed at increasing regulatory transparency, provides insight into common deficiencies cited by the agency during the approval process. While the release marks progress, the dataset includes only letters for approved products, limiting the scope of publicly available critiques. FDA Commissioner Marty Makary heralded the change as a step toward reducing uncertainty for developers and investors. However, portions of the CRLs remain redacted to protect proprietary information, and some question the completeness of this transparency initiative.